Patent 11261151
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Active provider: Google · gemini-2.5-flash
PTAB activity (1)
AIA trial proceedings — IPR, PGR, CBM — filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced directly from the PTAB Trial API.
- IPR2025-00799IPRfiled Apr 3, 2025vs. Intas Pharmaceuticals, Ltd. et al.Terminated-Settled
Cached for 24 hours. Status strings are sourced verbatim from the PTAB API; the colored badge is our heuristic classification.
Cases on file (1)
Group view →Specific litigation cases in our database that name US patent 11261151. The free-form analysis below may also discuss cases beyond this list.
- IPR2025-00799U.S. Patent and Trademark Office, Patent Trial and Appeal Board (PTAB)terminated Apr 16, 2026Settled
Defendants: Atossa Therapeutics, Inc. and Jina Pharmaceuticals, Inc.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Known litigation involving US patent 11261151 includes:
- Plaintiff(s): Intas Pharmaceuticals Ltd.
- Defendant(s): Atossa Therapeutics, Inc. and Jina Pharmaceuticals, Inc.
- Jurisdiction: U.S. Patent and Trademark Office, Patent Trial and Appeal Board (PTAB)
- Case Number: IPR2025-00799
- Filing Date: The case number IPR2025-00799 indicates it was filed in 2025.
- Outcome or current status: Settled. Atossa Therapeutics, Inc. announced a settlement agreement with Intas Pharmaceuticals Ltd. and Jina Pharmaceuticals, Inc. on April 16, 2026, to resolve patent disputes related to Endoxifen intellectual property, including this PTAB proceeding. The parties agreed to seek termination of the PTAB proceedings, and the patent is anticipated to remain issued and enforceable against third parties.
Generated 6/15/2026, 12:48:40 AM